BIA
DRUG

Bell Investment Advisors’s Bright Minds Biosciences DRUG Stock Holding History

Bell Investment Advisors’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$422 Hold
6
– – ﹤0.01% 1764
2026
Q1 		$438 Buy
+6
New +$483 ﹤0.01% 1796

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Bell Investment Advisors's DRUG Position: Q2 2026 in Review

Bell Investment Advisors held its Bright Minds Biosciences (DRUG) position steady in Q2 2026 at 6 shares worth $422. The position accounts for ﹤0.01% of the portfolio, ranked #1764.

Bell Investment Advisors first reported a position in DRUG in Q1 2026 and has held it in 2 quarters since. The position peaked at $438 in Q1 2026. 100 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • Bell Investment Advisors held 6 shares of Bright Minds Biosciences worth $422 as of Q2 2026.
  • Bell Investment Advisors left its Bright Minds Biosciences share count unchanged in Q2 2026.
  • Bright Minds Biosciences made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #1764 holding.
  • Bell Investment Advisors first reported a position in Bright Minds Biosciences in Q1 2026 and has held it in 2 quarters since.
  • Bell Investment Advisors's Bright Minds Biosciences position peaked at $438 in Q1 2026.
  • 100 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.